MARKET

EGRX

EGRX

Eagle Pharmaceut
EXMKT
0.450
+0.381
+553.59%
Closed 15:49 09/11 EDT
OPEN
0.600
PREV CLOSE
0.069
HIGH
0.600
LOW
0.450
VOLUME
400
TURNOVER
208
52 WEEK HIGH
3.210
52 WEEK LOW
0.068
MARKET CAP
5.84M
P/E (TTM)
0.494
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EGRX last week (0831-0904)?
Weekly Report · 5d ago
Weekly Report: what happened at EGRX last week (0824-0828)?
Weekly Report · 08/31 09:17
Weekly Report: what happened at EGRX last week (0817-0821)?
Weekly Report · 08/24 09:17
Weekly Report: what happened at EGRX last week (0810-0814)?
Weekly Report · 08/17 09:17
Weekly Report: what happened at EGRX last week (0803-0807)?
Weekly Report · 08/10 09:16
Weekly Report: what happened at EGRX last week (0727-0731)?
Weekly Report · 08/03 09:16
Weekly Report: what happened at EGRX last week (0720-0724)?
Weekly Report · 07/27 09:17
Weekly Report: what happened at EGRX last week (0713-0717)?
Weekly Report · 07/20 09:16
More
About EGRX
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.

Webull offers Eagle Pharmaceuticals Inc stock information, including EXMKT: EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.